Factor VIIi inhibitor and severity of hemophilia
Schoppmann, A.; Waytes, A.T.
Thrombosis and Haemostasis 76(2): 280-281
1996
ISSN/ISBN: 0340-6245 PMID: 8865549 Document Number: 469133
Document emailed within 1 workday
Related Documents
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J. 1982: The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor Journal of Medicine 13(5-6): 399-410
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Bolland, J.; Lambotte, C. 1978: Factor VIIi in hemophilia and von Willebrand's disease Revue Medicale de Liege 33(8): 284-295
Lopaciuk, S.; Ziemski, J.M. 1979: Treatment of patients with hemophilia a having antibodies to factor VIIi Acta Haematologica Polonica 10(2): 115-122
Hoyer, L.W.; Qian, J. 2000: Characterization of the immune response to factor VIIi using hemophilia A* mice Haematologica 85(10 Suppl): 100-102
Petrovic, M.; Derom, E.; Baele, G. 2000: Cyclosporine treatment of acquired hemophilia due to factor VIIi antibodies Haematologica 85(8): 895-896
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992